Research Triangle Park, N.C.-based CATO SMS and Bracknell, U.K.-headquartered Pharm-Olam, both providers of specialized clinical research services, announced today that they are merging to form a leading global biopharmaceutical services organization uniquely positioned to serve the growing number of small and mid-sized companies developing complex therapies.
Although smaller businesses currently account for nearly 70% of the biopharmaceutical industry’s intellectual property, they have often found it challenging to receive the full attention of senior resources required to effectively design and manage clinical studies. CATO SMS and Pharm-Olam are joining forces to address this gap and serve the specific needs of small and mid-sized businesses.
Read more about the merge here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.